Identification of potential prognostic microRNA biomarkers for predicting survival in patients with hepatocellular carcinoma

Xiwen Liao 1
Guangzi Zhu 1
Rui Huang 2
Chengkun Yang 1
Xiangkun Wang 1
Ketuan Huang 1
Tingdong Yu 1
Chuangye Han 1
Hao Su 1
Tao Peng 1

1 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China; 2 Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, People’s Republic of China

Background: The aim of the present study was to identify potential prognostic microRNA (miRNA) biomarkers for hepatocellular carcinoma (HCC) prognosis prediction based on a dataset from The Cancer Genome Atlas (TCGA).

Materials and methods: A miRNA sequencing dataset and corresponding clinical parameters of HCC were obtained from TCGA. Genome-wide univariate Cox regression analysis was used to screen prognostic differentially expressed miRNAs (DEMs), and multivariable Cox regression analysis was used for prognostic signature construction. Comprehensive survival analysis was performed to evaluate the prognostic value of the prognostic signature.

Results: Five miRNAs were regarded as prognostic DEMs and used for prognostic signature construction. The five-DEM prognostic signature performed well in prognosis prediction (adjusted \( P < 0.0001 \), adjusted hazard ratio = 2.249, 95% confidence interval = 1.491–3.394), and time-dependent receiver–operating characteristic (ROC) analysis showed an area under the curve (AUC) of 0.765, 0.745, 0.725, and 0.687 for 1-, 2-, 3-, and 5-year HCC overall survival (OS) prediction, respectively. Comprehensive survival analysis of the prognostic signature suggests that the risk score model could serve as an independent factor of HCC and perform better in prognosis prediction than other traditional clinical indicators. Functional assessment of the target genes of hsa-mir-139 and hsa-mir-5003 indicates that they were significantly enriched in multiple biological processes and pathways, including cell proliferation and cell migration regulation, pathways in cancer, and the cyclic adenosine monophosphate (cAMP) signaling pathway.

Conclusion: Our study indicates that the novel miRNA expression signature may be a potential prognostic biomarker for HCC patients.

Keywords: miRNA, TCGA, hepatocellular carcinoma, prognosis, biomarker

Introduction
Liver cancer is prevalent in People’s Republic of China and has become the fourth highest cancer-related death in Chinese males.1 The majority of liver cancers are diagnosed as hepatocellular carcinoma (HCC).2 Tumorigenesis is derived from environmental and genetic factors; therefore, with the completion of the human genome project, cancer genetic susceptibility has gained more and more attention. The genes in the genome that are dysregulated between tumors and normal tissues are the most promising source of diagnostic and prognostic biomarkers, as well as therapeutic targets.3–5 Like many other cancers, HCC is characterized by the dysregulation of multiple gene networks and signaling pathways that are ordinarily involved in tissue homeostasis. Both protein-coding genes and noncoding RNA genes are involved in these genetic effects. Although the intense investigation of protein-coding genes has been the focus,
microRNAs (miRNAs) are also receiving recognition as contributors to HCC. A miRNA is a small noncoding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses that functions in RNA silencing and posttranscriptional regulation of gene expression. The miRNA expression profiling of human cancer has identified miRNA expression signatures that are associated with cancer diagnosis, prognosis, staging, and treatment. Recently, miRNAs have been reported to play certain roles in HCC development, tumorigenesis, metastasis, clinical implication, and in the risk of hepatitis B virus (HBV) infection. Therefore, a comprehensive analysis of miRNA expression profiling in HCC with a reliable approach to developing clinical applications of miRNAs is highly necessary.

With the development of high-throughput sequencing technology and the completion of The Cancer Genome Atlas (TCGA) program, a large amount of genomic data is shared publicly for cancer research. TCGA has profiled and analyzed the whole-genome sequencing data at the DNA, RNA, protein, and epigenetic levels, and generated comprehensive, multidimensional maps of the key genomic changes in 33 types of cancer. These genomic data have been made publicly available, and help the cancer research community improve the prevention, diagnosis, and treatment of cancer. Comprehensive analysis of TCGA HCC whole-genome sequencing data has revealed the genomic characterization of HCC somatic mutations and developed a tumor protein p53 target gene expression signature that correlates with poor survival. However, comprehensive analysis of the miRNA prognostic signature still needs further investigation. The aim of the current study was to identify potential prognostic miRNA biomarkers for predicting survival in patients with HCC using TCGA datasets and bioinformatics analysis and to develop a miRNA expression-based prognostic signature.

Materials and methods

Data source

The HCC dataset, including Level 3 miRNA expression data, was downloaded from TCGA data portal (https://portal.gdc.cancer.gov/, accessed November 5, 2017). The corresponding clinical information was obtained from University of California, Santa Cruz Xena browser (UCSC Xena: http://xena.ucsc.edu/, accessed November 5, 2017). The raw counts of miRNA expression data of 375 tumor samples and 50 adjacent normal liver tissues were downloaded from TCGA dataset. Because the dataset in the current study was downloaded from TCGA, and data acquiring and application complied with the TCGA publication guidelines and data access policies, additional approval by an ethics committee was not needed.

Differentially expressed miRNA (DEM) screening

miRNA expression data were normalized by using the edgeR package on the R platform. The mean value of each miRNA greater than 0 was included in the screening of DEMs. A miRNA with a false discovery rate (FDR) < 0.05 and \(|\log_{2} FC| \geq 1\) of expression level between the comparison of HCC tumor and adjacent normal liver tissue was identified as DEM.

DEM expression-based prognostic signature construction

The prognostic value of miRNAs was first assessed by the univariate Cox proportional hazards regression that was performed using the survival package. These DEMs with a P-value < 0.001 were regarded as prognostic DEMs whose expression levels were significantly associated with the overall survival (OS) of HCC patients. These prognostic DEMs were assessed by the “step” function to select the optimal combination and then used for prognostic model construction. To evaluate the relative contribution of these prognostic DEMs to HCC survival prediction, they were fitted into a multivariate Cox regression analysis with OS as the dependent variable. A DEM expression-based prognostic risk score model was constructed by the linear combination of the expression levels of DEMs with the multivariate Cox regression coefficient (\(\beta\)) as the weight. The risk score formula was as follows: risk score = expression of DEM1 \(\times\) \(\beta_1\), DEM2 \(\times\) \(\beta_2\), DEM3 \(\times\) \(\beta_3\), ... expression of DEMn \(\times\) \(\beta_n\). This DEM prognostic model could divide the HCC patients into high- and low-risk groups using the median risk score that was based on DEM expression. The time-dependent receiver–operating characteristic (ROC) curve was performed using the survivalROC package on the R platform to evaluate the predictive accuracy of this DEM expression-based prognostic signature in HCC OS.

Comprehensive analysis of DEM expression-based prognostic signature

To comprehensively evaluate the prognostic model, comprehensive analysis of the DEM expression-based prognostic signature was carried out. In addition to the comparison of clinical outcomes between the low- and high-risk groups, we also investigated the prognosis predictive value of the risk score by nomogram, stratified analysis, and joint effect analysis.
analysis to evaluate the association between risk score and clinical status in HCC OS. Moreover, the potential application of risk score in clinical status prediction was also explored.

**Target prediction and enrichment analysis**

Targetscan\(^\text{18}\) (http://www.targetscan.org/, accessed November 5, 2017), miRDB\(^\text{19}\) (http://www.mirdb.org/, accessed November 5, 2017), and miRTarBase\(^\text{20}\) (http://mirtarbase.mbc.nctu.edu.tw/, accessed November 5, 2017) were used to predict miRNA target genes. The overlapping target genes among these three databases were identified as miRNA target genes and used for further enrichment analysis. Furthermore, miRNA target gene interaction networks were constructed with Cytoscape v3.4.0 (http://www.cytoscape.org/, accessed January 16, 2017). The potential function of these miRNA target genes was analyzed with the Database for Annotation, Visualization, and Integrated Discovery 6.8 (DAVID 6.8, https://david.ncifcrf.gov/home.jsp, accessed November 5, 2017) and visualized with the ggplot2 package.

**Statistical analysis**

Adjustment for multiple testing with the Benjamini–Hochberg procedure was used to control the FDR in edgeR. Univariate analysis between clinical features and OS were compared using the log-rank test; those with \(P < 0.05\) were entered into the multivariate Cox proportional hazards regression model for adjustment. A volcano plot and heat map were drawn by the ggplot2 package on the R platform. A value of \(P < 0.05\) was considered statistically significant. All statistical analyses were conducted with SPSS version 20.0 (IBM Corporation, Armonk, NY, USA) and R 3.3.0.

**Results**

**DEM screening**

A total of 1881 miRNAs were obtained from the Level 3 miRNA expression dataset, and 320 miRNAs (Table S1) were identified as DEMs after edgeR filtering, which meets the criterion of FDR < 0.05 and \(|\log2FC| \geq 1\). The volcano plot and heat map of these 320 DEMs were visualized by the ggplot2 package and shown in Figures 1 and 2, respectively.

**Construction of the DEM-based prognostic signature**

The univariate Cox regression analysis results of DEMs are shown in Table S2, and suggest that there were 17 DEMs gained significant prognostic value for HCC with a \(P\)-value less than 0.001. By analyzing the expression level of these DEMs, we found that five miRNAs (hsa-mir-137, hsa-mir-3680-2, hsa-mir-6728, hsa-mir-3660, and hsa-mir-2682) had low expression in tumor tissue, and more than 20% of samples had an expression of zero. Therefore, only the remaining 12 miRNAs were included in the step function screening to develop a miRNA prognostic model: hsa-mir-139, hsa-mir-101-2, hsa-mir-105-2, hsa-mir-9-3, and hsa-mir-5003. Kaplan–Meier and ROC curves of these prognostic DEMs are shown in Figures 3 and 4, respectively. A multivariate Cox regression analysis was used to test the relative contribution of these prognostic DEMs in survival prediction. The risk score formula was as follows: risk score = expression of hsa-mir-139 \(\times (-0.1795)\) + expression of hsa-mir-101-2 \(\times (-0.2396)\) + expression of hsa-mir-105-2 \(\times (0.0533)\) + expression of hsa-mir-9-3 \(\times (0.0728)\) + expression of hsa-mir-5003 \(\times (0.2640)\). Survival analysis of HCC clinical characteristics and risk scores are summarized in Table 1 and show that tumor stage and radical resection were significantly associated with HCC OS and were included into a multivariate Cox proportional hazards regression model for adjustment. Patients with a high-risk score have a shorter median survival time (MST) than those with a low-risk score (931 vs. 2456 days for high risk vs. low risk, Table 1, Figure 5A and B), and significantly increased risk of death (adjusted \(P < 0.0001\), adjusted hazard ratio = 2.249, 95% confidence interval [CI] = 1.491–3.394 for OS), after being adjusted...
for tumor stage and radical resection. Time-dependent ROC analysis with the survivalROC package demonstrated that this miRNA expression-based prognostic signature also performed well in HCC OS prediction; the area under the curve (AUC) of the time-dependent ROC curve was 0.765, 0.745, 0.725, and 0.687 for 1-, 2-, 3-, and 5-year survival (Figure 5C). The expression distribution of these miRNAs between tumor tissue and adjacent normal liver tissue is shown in Figure 6A, whereas the expression distribution in low- and high-risk groups is shown in Figure 6B. We also explored the potential use of this risk score in the status of clinical characteristic prediction, and the ROC curves are shown in Figure 7A–G. This 5-miRNA prognostic signature performed well in predicting HCC tumor stage ($P = 0.001$, AUC = 0.623, 95% CI = 0.552–0.694; Figure 7A), histologic grade ($P < 0.001$, AUC = 0.650, 95% CI = 0.593–0.706; Figure 7B), serum AFP ($P < 0.001$, AUC = 0.665, 95% CI = 0.590–0.740; Figure 7C), microvascular invasion ($P = 0.011$, AUC = 0.587, 95% CI = 0.519–0.654; Figure 7D), and radical resection ($P = 0.003$, AUC = 0.646, 95% CI = 0.558–0.735; Figure 7G).

Stratified and joint effects analysis
To further investigate the association between risk score and clinical characteristics in HCC OS, comprehensive survival analysis of nomogram, stratified, and joint effects survival analysis was carried out. The stratified analysis suggests that a high-risk score significantly increased the risk of death in patients with all favorable strata except in patients with G1 grade, without fibrosis and females, and all adverse strata except in patients with Child–Pugh B/C score, without radical resection, G1 grade, tumor stage II, and with alcohol consumption (Figure 8A), indicating that this 5-miRNA prognostic signature was independent of the clinical characteristics. A nomogram was drawn by rms and its auxiliary packages based on the data of 155 HCC patients with complete clinical information in TCGA. It substantiated that the 5-miRNA prognostic signature contributes the most risk points (ranged 0–100), whereas the other clinical characteristics contribute much less (Figure 8B).

Joint effects analysis of the 5-miRNA prognostic signature and clinical parameters indicate that this prognostic signature performed well in OS prediction and in combination with the clinical parameters showed a better predictive value for HCC OS (Figure 9A–G; Table 2).

Target prediction and enrichment analysis
To assess the potential biological function of the five miRNAs, the miRNA target genes were predicted by three independent miRNA target gene prediction websites: Targetscan, miRDB, and miRTarBase. The candidate target genes of each miRNA predicted in all three websites were identified as miRNA target genes. Because hsa-mir-9-3, hsa-mir-101-2, and hsa-mir-105-2 were not available in the Targetscan database, only the miRNA target genes of
hsa-mir-139 and hsa-mir-5003 were used for further enrichment analysis. A total of 36 genes were regarded as miRNA target genes for these two miRNAs and used for enrichment analysis and miRNA target gene interaction network construction. The miRNA target gene interaction networks are shown in Figure 10A. Functional assessment suggests that these miRNA target genes were significantly enriched in multiple biological processes, such as the regulation of cell proliferation and cell migration, cyclic adenosine monophosphate (cAMP) response element binding, response to drugs, and positive regulation of pri-miRNA transcription from RNA polymerase II promoter (Figure 10B). The Kyoto Encyclopedia of Genes and Genomes enrichment indicates that pathways in cancer, cAMP signaling pathway, proteoglycans in cancer, and focal adhesion were also significantly enriched (Figure 10C).

**Figure 3** The Kaplan–Meier curves of five prognostic DEMs in HCC. Notes: The order of Kaplan–Meier curves of five prognostic DEMs were as follows: hsa-mir-105-2 (A), hsa-mir-5003 (B), hsa-mir-101-2 (C), hsa-mir-139 (D), and hsa-mir-9-3 (E). **Abbreviations:** DEMs, differentially expressed microRNAs; HCC, hepatocellular carcinoma.
Figure 4 ROC curves of five prognostic DEMs to distinguish HCC tissue from adjacent normal liver tissue.

Notes: The order of ROC curves of five prognostic DEMs were as follows: hsa-mir-105-2 (A), hsa-mir-5003 (B), hsa-mir-101-2 (C), hsa-mir-139 (D), and hsa-mir-9-3 (E).

Abbreviations: AUC, area under the curve; CI, confidence interval; DEMs, differentially expressed microRNAs; HCC, hepatocellular carcinoma; ROC, receiver–operating characteristic.
Discussion

The data mining of TCGA miRNA datasets has been widely used in cancer prognosis prediction. Similar miRNA expression-based prognostic signatures for cancer prognosis prediction have been investigated in numerous studies. For instance, miRNA expression-based prognostic signatures, which were identified by Cox proportional regression models in cancer prognosis prediction using TCGA datasets, have been developed in multiple cancers, such as pancreatic cancer,26,27 stomach adenocarcinoma,28 head and neck squamous cell carcinoma,29,30 gliomas,31 glioblastoma,32–34 cervical cancer,35 bladder cancer,36 breast cancer,37,38 glioblastoma,39 lung cancer,40,41 and HCC.42–44 In addition, diagnostic45–47 and metastasis48 related miRNA signature biomarkers have been investigated in multiple cancers using TCGA datasets. Updates in the TCGA HCC dataset and the miRNA

Table 1 Distribution of HCC patients’ characteristics and prognosis analysis

| Variables                        | Events/total (n = 371) | MST (days) | Crude HR (95% CI) | Log-rank P |
|----------------------------------|------------------------|------------|-------------------|------------|
| Age (years)                      |                        |            |                   |            |
| ≤65                              | 72/233                 | 2456       | 1                 | 0.188      |
| >65                              | 56/138                 | 1490       | 1.265 (0.891–1.796) |            |
| Sex                              |                        |            |                   | 0.283      |
| Female                           | 49/119                 | 1560       | 1                 |            |
| Male                             | 79/252                 | 2486       | 0.822 (0.574–1.176) |            |
| Alcohol consumptiona             |                        |            |                   | 0.733      |
| No                               | 82/235                 | 1852       | 1                 |            |
| Yes                              | 40/117                 | 1624       | 1.068 (0.731–1.561) |            |
| Ishak fibrosis scoreb            |                        |            |                   | 0.794      |
| 0 - no fibrosis                  | 30/75                  | 2456       | 1                 |            |
| 1,2 - portal fibrosis            | 9/30                   | 1372       | 0.964 (0.451–2.062) |            |
| 3,4 - fibrous spetsa             | 6/30                   | NA         | 0.616 (0.254–1.494) |            |
| 5 - nodular formation and incomplete cirrhosis | 2/9                   | 1386       | 0.754 (0.178–3.184) |            |
| 6 - established cirrhosis        | 17/70                  | NA         | 0.765 (0.417–1.401) |            |
| Tumor stagec                     |                        |            |                   | <0.0001    |
| I                                | 42/172                 | 2532       | 1                 |            |
| II                               | 26/85                  | 1852       | 1.466 (0.896–2.398) |            |
| III–IV                           | 47/90                  | 770        | 2.808 (1.844–4.278) |            |
| Histologic gradezd               |                        |            |                   | 0.858      |
| G1                               | 18/55                  | 2116       | 1                 |            |
| G2                               | 59/176                 | 1694       | 1.167 (0.688–1.979) |            |
| G3                               | 43/123                 | 1622       | 1.205 (0.694–2.091) |            |
| G4                               | 5/13                   | NA         | 1.486 (0.549–4.023) |            |
| Serum AFPe                       |                        |            |                   | 0.788      |
| ≤400 ng/mL                       | 62/216                 | 2456       | 1                 |            |
| >400 ng/mL                       | 22/64                  | 2486       | 1.070 (0.654–1.750) |            |
| Radical resectionf               |                        |            |                   | 0.004      |
| R0                               | 108/324                | 2116       | 1                 |            |
| R1–R2+RX                        | 17/40                  | 837        | 2.082 (1.244–3.486) |            |
| MVIg                             |                        |            |                   | 0.162      |
| No                               | 59/206                 | 2131       | 1                 |            |
| Yes                              | 36/110                 | 2486       | 1.344 (0.886–2.039) |            |
| Child–Pugh scoreh                |                        |            |                   | 0.164      |
| A                                | 59/219                 | 3125       | 1                 |            |
| B+C                              | 9/22                   | 1005       | 1.644 (0.811–3.331) |            |
| Risk score                       |                        |            |                   | <0.0001    |
| Low                              | 43/186                 | 2456       | 1                 |            |
| High                             | 85/185                 | 931        | 2.667 (1.845–3.856) |            |

Notes: aInformation of alcohol consumption was unavailable in 19 patients; binformation of Ishak fibrosis score was unavailable in 157 patients; cinformation of tumor stage was unavailable in 24 patients; dinformation of histologic grade was unavailable in 4 patients; einformation of serum AFP was unavailable in 91 patients; finformation of radical resection was unavailable in 7 patients; ginformation of MVI was unavailable in 55 patients; hinformation of Child–Pugh score was unavailable in 130 patients.

Abbreviations: AFP, α-fetoprotein; CI, confidence interval; HCC, hepatocellular carcinoma; HR, hazard ratio; MST, median survival time; MVI, microvascular invasion; NA, not available.
expression-based prognostic signatures require comprehensive survival analysis to validate; therefore, further investigations of miRNA expression prognostic signatures with a reliable method and comprehensive evaluation is necessary. The advantage of the current study was that the optimum combination of these prognostic miRNAs was investigated.

**Figure 5** Prognostic risk score model analysis of five prognostic DEMs in HCC patients.

**Notes:** (A) From top to bottom are the risk score, patients’ survival status distribution, and five prognostic DEMs’ expression heat map for low- and high-risk groups. (B) Kaplan–Meier curves for low- and high-risk groups. (C) ROC curve for predicting survival in HCC patients by the risk score.

**Abbreviations:** DEMs, differentially expressed microRNAs; HCC, hepatocellular carcinoma; ROC, receiver–operating characteristic.

**Figure 6** Expression level of five prognostic DEMs in tumor tissue and adjacent normal liver tissue, low- and high-risk groups, respectively.

**Notes:** (A) Scatter plot of five prognostic DEMs’ expression level between HCC tumor tissue and adjacent normal liver tissue. (B) Scatter plot of five prognostic DEMs’ expression level between low- and high-risk groups; *P<0.05; ****P<0.0001.

**Abbreviations:** DEMs, differentially expressed microRNAs; HCC, hepatocellular carcinoma.
Previous studies report that miR-9-3 was found to be specifically methylated in tumors of patients with non-small cell lung cancers and serves as a prognostic marker. Moreover, aberrant miR-9-3 methylation was associated with tumor progression.\(^5\) Aberrant methylation of miR-9-3 has also been reported in bladder cancer,\(^6\) clear cell renal cell carcinoma,\(^6\) oral and oropharyngeal squamous cell carcinomas,\(^6\) HCC,\(^6\) and thymoma and thymic carcinoma.\(^6\) In addition, hypermethylation of miR-9-3 was a potential diagnostic marker in bladder cancer\(^6\) and HCC,\(^6\) whereas miR-9-3 methylation status was also significantly associated with OS in HCC\(^6\) and increased risk of recurrence in clear cell renal cell carcinoma.\(^6\) In the current study, we focused on investigating the association between the expression of hsa-mir-9-3 and clinical outcome; therefore, the hsa-miR-9-3 methylation status was also significantly associated with OS in HCC\(^6\) and further analysis. Although the current study did not mine the methylation data of hsa-mir-9-3 using TCGA datasets, our study was the first study to reveal the value of hsa-mir-9-3 expression in HCC prognosis and diagnosis.

Hsa-mir-101-2 is encoded by a gene located in 9p21; studies by Ma et al reveal that miR-101-2-5p was involved in lipid metabolism through binding with the 3’-untranslated region of the ApoB gene in the liver of egg-laying chickens.\(^6\) Furthermore, work by Bae et al suggests that genetic variations...
of miR-101-2 had a significant association with the clearance of HBV infection. In cancer research, genetic variations of miR-101-2 were associated with significantly increased risk of genetic susceptibility in breast cancer. Functional research in gastric cancer indicates that miR-101-2 was notably downregulated in gastric cancer tumor tissues and acts as a potential tumor suppressor in gastric cancer. Inhibited expression of miR-101-2 significantly reduced cell viability and colony formation, increased cell death, and reduced cell migration and invasion in gastric cancer cells. A similar data mining study of TCGA in breast cancer demonstrated that miR-101-2 was downregulated in breast cancer tumor tissue, and may be a potential biomarker for the prognosis and diagnosis of breast cancer. Additionally, the expression level of miR-101-2 was associated with the clinical parameters of tumor progression. In the present study, we also observed...
miR-101-2 downregulation in HCC tumor tissue and low miR-101-2 expression were significantly associated with poor clinical outcome, which is consistent with previous studies. However, presently, the functional verification experiments of miR-101-2 in HCC have not been reported and still need to be further confirmed. Hsa-mir-9-3, hsa-mir-101-2, and...
Table 2 | Joint effects survival analysis of clinical factors and the DEMs' signature risk score with OS in HCC patients

| Group | Risk score | Variables | Events/total (n = 370) | MST (days) | Crude HR (95% CI) | Crude $^P$ | Adjusted HR (95% CI) | Adjusted $^P$ |
|-------|------------|-----------|-----------------------|-----------|-------------------|-----------|----------------------|-------------|
| A     | Low risk   | Stage I   | 14/100                | NA        | 1                 | 1         | 1                    | 1           |
| B     | Low risk   | Stage II  | 6/38                  | 3258      | 1.259 (0.535–2.963) | 0.598     | 1.265 (0.537–2.979) | 0.59        |
| C     | Low risk   | Stage III-IV | 13/34               | 1622      | 1.888 (0.888–4.012) | 0.099     | 1.894 (0.891–4.027) | 0.097       |
| D     | High risk  | Stage I   | 28/71                 | 1372      | 2.182 (1.181–4.031) | 0.013     | 2.160 (1.169–3.992) | 0.014       |
| E     | High risk  | Stage II  | 20/47                 | 848       | 2.547 (1.368–4.743) | 0.003     | 2.525 (1.356–4.702) | 0.004       |
| F     | High risk  | Stage III-IV | 35/56             | 419       | 3.342 (3.112–9.170) | <0.001    | 4.857 (2.783–8.457) | <0.001      |

**Histologic grade**

| a     | Low risk | G1        | 8/37                  | 2131      | 1                 | 1         | 1                    | 1           |
| b     | Low risk | G2        | 18/95                 | 3125      | 1.063 (0.512–2.207) | 0.869     | 1.107 (0.496–2.472) | 0.803       |
| c     | Low risk | G3+G4    | 10/49                 | NA        | 0.492 (0.178–1.357) | 0.171     | 0.559 (0.193–1.618) | 0.283       |
| d     | High risk | G1      | 10/18                 | 581       | 2.029 (0.886–4.648) | 0.094     | 1.752 (0.685–4.483) | 0.242       |
| e     | High risk | G2      | 42/82                 | 802       | 2.289 (1.126–4.655) | 0.022     | 1.970 (0.888–4.371) | 0.095       |
| f     | High risk | G3+G4  | 38/84                 | 899       | 2.431 (1.207–4.897) | 0.013     | 2.183 (1.001–4.760) | 0.0496      |

**Serum AFP**

| I     | Low risk | ≤400 ng/mL | 20/121             | 2532      | 1                 | 1         | 1                    | 1           |
| II    | Low risk | >400 ng/mL | 6/26                | NA        | 0.622 (0.189–2.049) | 0.435     | 0.439 (0.105–3.403) | 0.262       |
| III   | Low risk | ≤400 ng/mL | 42/92              | 1149      | 2.243 (1.355–3.712) | 0.002     | 1.982 (1.154–3.403) | 0.013       |
| IV    | High risk | >400 ng/mL | 16/38              | 2486      | 1.990 (1.105–3.584) | 0.022     | 1.762 (0.945–3.283) | 0.075       |

**Microvascular invasion**

| i     | Low risk | No        | 23/119             | 3125      | 1                 | 1         | 1                    | 1           |
| ii    | Low risk | Yes       | 11/50              | 3258      | 1.022 (0.476–2.191) | 0.956     | 0.727 (0.298–1.774) | 0.484       |
| iii   | Low risk | No        | 37/87              | 1372      | 2.319 (1.381–3.894) | 0.001     | 1.958 (1.128–3.400) | 0.017       |
| iv    | High risk | Yes      | 25/58              | 1149      | 2.968 (1.714–5.142) | <0.001    | 2.236 (1.139–4.391) | 0.019       |

**Child–Pugh score**

| 1     | Low risk | A         | 21/116             | 3258      | 1                 | 1         | 1                    | 1           |
| 2     | Low risk | B+C       | 3/13               | 2386      | 2.277 (1.348–3.848) | 0.002     | 2.237 (1.296–3.861) | 0.004       |
| 3     | High risk | A         | 38/100             | 1386      | 2.430 (1.947–4.818) | 0.065     | 2.245 (1.29–4.72)   | 0.081       |
| 4     | High risk | B+C       | 6/9                | 535       | 2.862 (1.849–9.515) | 0.09      | 2.201 (0.641–7.554) | 0.21        |

**Ishak fibrosis score**

| I     | Low risk | 0         | 13/47              | 3125      | 1                 | 1         | 1                    | 1           |
| 2     | Low risk | 1/2/3/4/5/6 | 13/77          | NA        | 0.912 (0.414–2.010) | 0.82     | 1.006 (0.435–2.324) | 0.99        |
| 3     | High risk | 0         | 17/27              | 660       | 2.381 (1.123–5.045) | 0.024     | 2.169 (0.977–4.819) | 0.057       |
| 4     | High risk | 1/2/3/4/5/6 | 21/60           | 1372      | 1.836 (0.849–3.974) | 0.123     | 2.079 (0.915–4.722) | 0.081       |

**Radical resection**

| I     | Low risk | R0        | 33/169             | 3125      | 1                 | 1         | 1                    | 1           |
| 22    | Low risk | R1+R2+RX | 6/14               | 837       | 1.308 (0.315–5.423) | 0.712     | 1.501 (0.359–6.280) | 0.578       |
| 33    | High risk | R0       | 77/154             | 802       | 2.430 (1.645–3.589) | <0.001    | 2.263 (1.482–3.456) | <0.001      |
| 44    | High risk | R1+R2+RX | 11/26              | 837       | 4.154 (2.288–7.542) | <0.001    | 3.081 (1.533–6.191) | 0.002       |

**Notes:** *Information of tumor stage was unavailable in 24 patients; *information of histologic grade was unavailable in 91 patients; *information of microvascular invasion was unavailable in 55 patients; *information of serum AFP was unavailable in 91 patients; *information of Child–Pugh score was unavailable in 130 patients; *information of Ishak fibrosis score was unavailable in 157 patients; *information of radical resection was unavailable in 7 patients; *adjusted for tumor stage and radical resection.

**Abbreviations:** AFP, α-fetoprotein; CI, confidence interval; DEMs, differentially expressed microRNAs; HCC, hepatocellular carcinoma; HR, hazard ratio; MST, median survival time; NA, not available; OS, overall survival.

hsa-mir-105-2 have not been reported in previous studies, and their function still needs further investigation.

Functional assessment of the target genes of hsa-mir-139 and hsa-mir-5003 suggests that these target genes were significantly enriched in the regulation of cell-based biological processes, such as cell proliferation and cell migration. Recently, miR-139 has been reported as a tumor suppressor in various types of cancer and can regulate many cancer-related genes and pathways that affect the cell function.52–74 Previous experimental studies have substantiated that overexpression of miR-139 expression in HCC cell lines can inhibit cell proliferation, migration, and invasion through regulating multiple genes and pathways.52,53,55,56 MiR-139 downregulation increased the invasive abilities of HCC cells in vitro and HCC metastasis in vivo.54 These reports conclude that the function of miR-139 may be a potential tumor suppressor in
Figure 10 The prognostic miRNAs-target genes interactions network and their enrichment analysis results.  
Notes: (A) The prognostic miRNAs-target genes interactions network. (B) GO term enrichment results. (C) KEGG enrichment results.  
Abbreviations: GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
HCC and may provide a therapeutic strategy for the treatment of HCC patients, especially for HCC tumor metastasis.54–56 By reviewing the literature, we failed to retrieve the relevant reports on the function of hsa-mir-5003 in cell proliferation and migration in biological processes.

In the current study, through a comprehensive survival analysis of the prognostic signature, we have developed an accurate risk score model for HCC prognosis prediction based on the expression of five miRNAs. The risk score of patients with HCC can be divided into high- and low-risk groups, and the clinical outcome of HCC patients was significantly different between high- and low-risk groups. Time-dependent ROC analysis also suggested that this risk score model has long-term prognosis prediction and has relatively good accuracy. Stratified analysis revealed that this risk score model was an independent factor of HCC, while joint effects analysis and nomogram indicated that the risk score model performed better than traditional prognostic markers. Although this model performs well in HCC prognosis prediction, there are some limitations in the current study that still need clarification. First, because the clinical parameters from the TCGA database were not complete, such as the detailed information of treatment after the surgery was not available, we therefore could not perform a comprehensive survival analysis of the miRNA expression-based prognostic signature that considered all the potential prognostic factors of HCC. Second, patients in the current study were exclusively from a single cohort with a relatively small sample size, which may serve to bias our results. In addition, our sample size was not large enough to accurately validate the impact of the prognostic signature on OS in all strata of the stratified analysis. Therefore, our findings still need further verification in independent larger cohorts.

Despite these limitations, our current study has identified numerous DEMs, which may have potential value in HCC diagnosis and prognosis. We also constructed an effective prognostic signature to predict HCC prognosis that may have value in potential clinical applications.

**Conclusion**

Our study has identified 320 DEMs between HCC tumor tissue and adjacent normal liver tissue and assessed their predictive value in HCC prognosis. Five of the DEMs (hsa-mir-139, hsa-mir-101-2, hsa-mir-105-2, hsa-mir-9-3, and hsa-mir-5003) were used for prognostic signature construction based on their expression level. Survival analysis indicates that this five-DEM prognostic signature was significantly associated with HCC OS, and time-dependent ROC analysis also revealed that the prognostic signature showed a good performance in HCC survival prediction with the AUC of 0.765, 0.745, 0.725, and 0.687 for 1-, 2-, 3-, and 5-year survival, respectively. Stratified analysis substantiated that the prognostic signature serves as an independent factor of HCC and performs better in prognosis prediction than other traditional clinical indicators. Joint effects analysis demonstrated that a combination of this prognostic signature and other clinical indicators could obviously improve the performance of HCC prognosis prediction, and the nomogram also revealed that the prognostic signature contributed more than other traditional clinical indicators in HCC prognosis prediction. In addition, these five DEMs may serve as a potential independent risk factor and prognosis indicator for HCC patients and may also have potential diagnostic and prognostic value in HCC. However, due to limitations in our study, validation of our findings is necessary with independent cohorts. Moreover, additional findings obtained in our study are also worthy of further investigation.

**Acknowledgments**

This work was supported in part by the National Nature Science Foundation of China (81560535, 81072321, 30760243, 30460143, and 30560133), 2009 Program for New Century Excellent Talents in University (NCET), Guangxi Nature Sciences Foundation (GuiKeGong 1104003A-7), and Guangxi Health Ministry Medicine Grant (Key-Scientific Research-Grant ZZ01018). The present study is also partly supported by Scientific Research Fund of the Health and Family Planning Commission of Guangxi Zhuang Autonomous Region (ZZ016318). We would also acknowledge the supported provided by the National Key Clinical Specialty Programs (General Surgery and Oncology) and the Key Laboratory of Early Prevention and Treatment for Regional High-Incidence-Tumor (Guangxi Medical University), Ministry of Education, China. The authors thank the contributors of TCGA (https://cancergenome.nih.gov/) and UCSC Xena (http://xena.ucsc.edu) for sharing the HCC data on open access. In addition, we would like to acknowledge the helpful comments on this article received from our reviewers.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**

1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
2. Tang D, Nagano H, Nakamura M, et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. J Gastrointest Surg. 2006;10(7):987–998.
3. George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 2015;35(1):63–74.
4. Klingenberg M, Matsuda A, Diedrichs S, Patel T. Non-coding RNA in hepatocellular carcinoma: mechanisms, biomarkers and therapeutic targets. J Hepatol. 2017;67(3):603–618.
5. Shibata C, Otsuka M, Kishikawa T, et al. Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol. 2015;7(1):1–6.
6. Ambros V. The functions of animal microRNAs. Nature. 2004;431(7006):350–355.
7. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
8. Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn. 2011;11(8):813–827.
9. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
10. Wang Z, Li X. The role of noncoding RNA in hepatocellular carcinoma. Gland Surg. 2013;2(1):25–29.
11. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The Cancer Genome Atlas pan-cancer analysis project. Nat Genet. 2013;45(10):1131–1120.
12. Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn. 2011;11(8):813–827.
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
14. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Biostatistics. 2010;11(1):3–23.
15. Liao X, Huang K, Huang R, et al. Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Onco Targets Ther. 2017;10:4493–4506.
16. Zhou M, Zhao H, Wang Z, et al. Identification and validation of potential prognostic IncRNA biomarkers for predicting survival in patients with multiple myeloma. J Exp Clin Cancer Res. 2015;34:102.
17. Zhou M, Sun Y, Sun Y, et al. Comprehensive analysis of IncRNA expression profiles reveals a novel IncRNA signature to discriminate nonequivalent outcomes in patients with ovarian cancer. Oncotarget. 2016;7(22):32433–32448.
18. Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:1–38.
19. Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–D152.
20. Chou CH, Shrestha S, Yang CD, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(Database issue):D296–D302.
21. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
22. Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol. 2003;4(5):P3.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Series B Stat Methodol. 1995;57(1):289–300.
24. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19(3):368–375.
25. Benjamini Y, Drai D, Elmer G, Kaifafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125(1–2):279–284.
26. Liang L, Wei DM, Li JJ, et al. Prognostic microRNAs and their potential molecular mechanism in pancreatic cancer: a study based on The Cancer Genome Atlas and bioinformatic investigations. Mol Med Rep. 2018;17(1):939–951.
27. Zhou X, Huang Z, Xu L, et al. A panel of 13-miRNA signature as a potential biomarker for predicting survival in pancreatic cancer. Oncotarget. 2016;7(43):6986–6994.
28. Ding B, Gao X, Li H, Liu L, Hao X. A novel microRNA signature predicts survival in stomach adenocarcinoma. Oncotarget. 2017;8(17):28144–28153.
29. Wang N, Khwaja SS, Baker CM, et al. Prognostic microRNA signatures derived from The Cancer Genome Atlas for head and neck squamous cell carcinomas. Cancer Med. 2016;5(7):1619–1628.
30. Shi H, Chen J, Li Y, et al. Identification of a six microRNA signature as a novel potential prognostic biomarker in patients with head and neck squamous cell carcinoma. Oncotarget. 2016;7(16):21579–21590.
31. Yan W, Li R, Liu Y, et al. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014;5(24):12908–12915.
32. Li R, Gao K, Luo H, et al. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma. J Exp Clin Cancer Res. 2014;33:9.
33. Wang X, Bao Z, Yan W, et al. Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type. J Exp Clin Cancer Res. 2013;32:59.
34. Hayes J, Thysgesen H, Tunnilson C, et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Mol Oncol. 2015;9(3):704–714.
35. Liang B, Li Y, Wang T. A three miRNAs signature predicts survival in cervical cancer using bioinformatics analysis. Sci Rep. 2017;7(1):5624.
36. Zhou H, Tang K, Xiao H, et al. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res. 2015;34:53.
37. Zhou X, Wang X, Huang Z, Xu L, Zhu W, Liu P. An ER-associated microRNA signature predicts prognosis in ER-positive breast cancer. J Exp Clin Cancer Res. 2014;33:94.
38. Volinia S, Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proc Natl Acad Sci U S A. 2013;110(18):7413–7417.
39. Jacob H, Stanisavljevic L, Storli KE, Hestetun KE, Dahl O, Myklebust MP. Identification of a sixteen-microRNA signature as prognostic biomarker for stage II and III colon cancer. Oncotarget. 2017;8(50):87837–87847.
40. Li X, Shi Y, Yin Z, Xue X, Zhao B. An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma. J Transl Med. 2014;12:159.
41. Gao X, Wu Y, Yu W, Li H. Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma. Oncotarget. 2016;7(49):81670–81679.
42. Lu M, Kong X, Wang H, Huang G, Ye C, He Z. A novel microRNAs expression signature for hepatocellular carcinoma diagnosis and prognosis. Oncotarget. 2017;8(5):8775–8784.
43. Liu G, Wang H, Fu JD, Liu JY, Yan AG, Guan YY. A five-miRNA expression signature predicts survival in hepatocellular carcinoma. APMIS. 2017;125(7):614–622.
44. Zhang J, Chong CC, Chen GG, Lai PB. A seven-microRNA expression signature predicts survival in hepatocellular carcinoma. PLoS One. 2015;10(6):e0128628.
45. Zhou X, Wen W, Zhu J, et al. A six-microRNA signature in plasma identified as a potential biomarker in diagnosis of esophageal squamous cell carcinoma. Oncotarget. 2016;7(21):34468–34480.
46. Zhang Y, Sui J, Shen X, et al. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer. Oncol Rep. 2017;37(6):3543–3553.
47. Xiong DD, Lv J, Wei KL, et al. A nine-miRNA signature as a potential diagnostic marker for breast carcinoma: an integrated study of 1,110 cases. Oncol Rep. 2017;37(6):2597–3004.

48. Ab Mutalib NS, Othman SN, Mohamad Yusof A, Abdullah Suhaimi SN, Muhammad R, Jamal R. Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer. Cancer Sci. 2011;102(12):2126–2131.

49. Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57(2):840–847.

50. Zhang Q, Pu R, Du Y, et al. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets. Cancer Lett. 2012;321(1):1–12.

51. Li T, Yin J, Yuan L, et al. Downregulation of microRNA-139 is associated with hepatocellular carcinoma risk and short-term survival. Oncol Rep. 2014;31(4):1699–1706.

52. Wang Z, Ding Q, Li Y, et al. MicroRNAs is associated with tumor size and recurrence of non-small cell lung cancers. Int J Clin Exp Pathol. 2015;8(10):17261–17270.

53. Gu W, Li X, Wang J. miR-139 regulates the proliferation and invasion of hepatocellular carcinoma through the WNT/TCF-4 pathway. Oncol Rep. 2014;31(1):397–404.

54. Wong CC, Wong CM, Tung EK, et al. Reanalysis of microRNA expression profiles based on The Cancer Genome Atlas (TCGA) and bioinformatics. Cell Oncol (Dordr). 2016;39(1):23–33.

55. Qiu G, Lin Y, Zhang H, Wu D. miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. Biochem Biophys Res Commun. 2015;463(3):315–321.

56. Fan Q, He M, Deng X, et al. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. Cell Biochem Funct. 2013;31(4):319–324.

57. Wang M, Wen TF, He LH, Li C, Zhu WJ, Trishul NM. A six-microRNA set as prognostic indicators for bile duct cancer. Int J Clin Exp Med. 2015;8(10):17261–17270.

58. Liu X, Duan B, Dong Y, et al. MicroRNA-139-3p indicates a poor prognosis of colon cancer. Int J Clin Exp Pathol. 2014;7(11):8046–8052.

59. Heller G, Weinzirl M, Noll C, et al. Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res. 2012;18(6):1619–1629.

60. Kitano K, Watanabe K, Emoto N, et al. CpG island methylation of microRNAs is associated with tumor size and recurrence of non-small cell lung cancer. Cancer Sci. 2011;102(12):2126–2131.

61. Shimizu T, Suzuki H, Nojima M, et al. Methylation of a panel of microRNA genes is a novel biomarker for detection of bladder cancer. Eur Urol. 2013;63(6):1091–1100.

62. Hildebrandt MA, Gu J, Lin J, et al. Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. Oncogene. 2010;29(42):5724–5728.

63. Minor J, Wang X, Zhang F, et al. Methylation of microRNA-9 is a specific and sensitive biomarker for oral and oropharyngeal squamous cell carcinomas. Oral Oncol. 2012;48(1):73–78.

64. Potapova A, Albat C, Hasemeier B, et al. Systematic cross-validation of 454 sequencing and pyrosequencing for the exact quantification of DNA methylation patterns with single CpG resolution. BMC Biotechnol. 2011;11:6.

65. Anwar SL, Albat C, Krech T, et al. Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker. Int J Cancer. 2013;133(3):660–670.

66. Enkner F, Pichlhöfer B, Zaharie AT, et al. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res. 2017;23(3):551–564.

67. Ma Z, Li H, Zheng H, et al. MicroRNA-101-2-5p targets the ApoB gene in the liver of chicken (Gallus Gallus). Genome. 2017;60(8):673–678.

68. Bae JS, Kim JH, Pasaje CF, et al. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis. 2012;44(10):849–854.

69. Chen J, Qin Z, Jiang Y, et al. Genetic variations in the flanking regions of miR-101-2 are associated with increased risk of breast cancer. PLoS One. 2014;9(1):e86319.

70. Riquelme I, Tapia O, Leal P, et al. miR-101-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr). 2016;39(1):23–33.

71. Li CY, Xiong DD, Huang CQ, et al. Clinical value of miR-101-3p and miR-125b-2 and miR-451a in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis. 2012;44(10):849–854.

72. Enkner F, Pichlhöfer B, Zaharie AT, et al. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res. 2017;23(3):551–564.

73. Yang L, Yin D, Wang Y, Cao L. Inhibition of the growth of hepatocellular carcinoma cells through fibroblast growth factor 18 suppressed proliferation and self-renewal by targeting the Bmi1 oncogene. Tumour Biol. 2017;39(7):1010428317718414.
Supplementary materials

**Table S1** DEMs identified by the edgeR package.
**Abbreviation:** DEMs, differentially expressed microRNAs.

**Table S2** The univariate survival analysis results of the DEMs.
**Abbreviation:** DEMs, differentially expressed microRNAs.